Valuation: Orexo AB

Market Cap 464M 47.86M 41.24M 39.05M 35.39M 66.4M 4.57B 66.73M 178M 2.33B 180M 176M 7.35B P/E 2026 *
-1.27x
P/E 2027 * -1.82x
Enterprise Value 359M 37.03M 31.9M 30.21M 27.38M 51.37M 3.54B 51.63M 138M 1.8B 139M 136M 5.69B EV / Sales 2026 *
18.9x
EV / Sales 2027 * 17.2x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-0.23%
1 week-9.80%
Current month-15.54%
1 month-12.76%
3 months-37.89%
6 months-43.21%
Current year-55.95%
1 week 13
Extreme 13
14.92
1 month 12.9
Extreme 12.9
16.6
Current year 12.9
Extreme 12.9
36
1 year 12.9
Extreme 12.9
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/25 Buy

Chief Executive Officer

6 0.0000%
4/9/25 Free

Chief Executive Officer

1,393 0.0040%
3/9/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%-9.80%-49.87%-24.40% 47.86M
-0.54%-4.26%+73.81%+33.50% 355B
+1.64%-0.96%+25.40%-18.81% 66.33B
+0.19%-2.71%+39.40%+161.27% 12.17B
+1.55%-6.88%-7.27%-17.48% 7.47B
-4.80%-8.31%-28.47%-8.74% 4.64B
+0.63%-2.46%-33.67%+12.81% 4.42B
-1.24%-6.98%-35.59%-10.53% 2.86B
-0.12%-4.34%-8.40%+38.66% 2.42B
-1.84%-5.00%-28.40%-26.72% 1.9B
Average -0.32%-5.38%-5.31%+13.96% 45.74B
Weighted average by Cap. +1.02%-4.15%+60.91%+27.35%

Financials

2026 *2027 *
Net sales 19M 1.96M 1.69M 1.6M 1.45M 2.72M 187M 2.73M 7.31M 95.31M 7.36M 7.2M 301M 27M 2.79M 2.4M 2.27M 2.06M 3.87M 266M 3.89M 10.38M 135M 10.47M 10.24M 428M
Net income -375M -38.7M -33.35M -31.57M -28.62M -53.69M -3.7B -53.96M -144M -1.88B -145M -142M -5.94B -
Net Debt -105M -10.84M -9.34M -8.84M -8.01M -15.03M -1.04B -15.11M -40.38M -527M -40.7M -39.8M -1.66B -
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
14/09/26 SEK 13.26 -0.15% 19,011
11/09/26 SEK 13.28 -0.90% 35,980
10/09/26 SEK 13.40 +0.75% 75,077
09/09/26 SEK 13.30 -3.48% 25,899
08/09/26 SEK 13.78 -6.26% 67,592
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!